AACR: mRNA-4157 Plus Pembrolizumab Beneficial in Melanoma

MONDAY, April 17, 2023 -- For patients with completely resected, high-risk cutaneous melanoma, the novel mRNA-based cancer vaccine (mRNA-4157) combined with pembrolizumab results in improved recurrence-free survival (RFS) compared with pembrolizumab...